Amended Current Report Filing (8-k/a)
April 12 2019 - 4:36PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1
To
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 11, 2019
CHINA JO-JO DRUGSTORES, INC.
(Exact name of Registrant as specified in charter)
Nevada
|
|
001-34711
|
|
98-0557852
|
(State or other jurisdiction
of Incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer
Identification No.)
|
Hai Wai Hai Tongxin Mansion Floor 6 Gong Shu District
Hangzhou City, Zhejiang Province, People’s
Republic of China, 310008
(Address of principal executive offices) (Zip
Code)
Registrant's telephone number, including area
code:
+86 (571) 88219579
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to
Rule 425 under the Securities Act (17CFR230.425)
☐ Soliciting material pursuant to Rule14a-12
under the Exchange Act (17CFR240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
On April 11, 2019, China
Jo-Jo Drugstores, Inc. (the “Company”) filed a current report on Form 8-K reporting the entry into certain Securities
Purchase Agreement for the offering of 4,000,008 shares of the common stock (the “Shares”) from the Company’s
effective shelf registration statement on Form S-3 (File No. 333-230686), which was originally filed with the Securities and Exchange
Commission on April 2, 2019 and was declared effective on April 10, 2019 and a concurrent private placement of warrants to purchase
up to an aggregate of 3,000,006 shares of the common stock (the “Original Form 8-K”). This Amendment No. 1 to the Original
Form 8-K is herein filed solely for the purpose of filing the exhibits including Exhibit 5.1 opinion letter regarding the validity
of the Shares to be issued at the closing of the offering referenced above.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: April 12, 2019
|
CHINA JO-JO DRUGSTORES, INC.
|
|
|
|
|
By:
|
/s/ Lei Liu
|
|
Name:
|
Lei Liu
|
|
Title:
|
Chief Executive Officer
|
China Jo Jo Drugstores (NASDAQ:CJJD)
Historical Stock Chart
From Mar 2024 to Apr 2024
China Jo Jo Drugstores (NASDAQ:CJJD)
Historical Stock Chart
From Apr 2023 to Apr 2024